CTOs on the Move

MicroCal

www.microcal.com

 
MicroCal, LLC is a Northampton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.microcal.com
  • 22 Industrial Dr E
    Northampton, MA USA 01060
  • Phone: 413.586.7720

Executives

Name Title Contact Details

Similar Companies

Omni-Tract Surgical

Omni-Tract Surgical is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gereonics

Gereonics is a Solana Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

eScan Data Systems

eScan Data Systems is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthCube

HealthCube ensures that accurate diagnosis is within easy and convenient reach of billions of people in both developed and developing economies. HealthCube designs and manufactures point-of-care diagnostic devices to enhance the quality of primary care in diverse settings. HealthCube`s multiparametric technology can test for over 30 parameters including blood glucose, hemoglobin, blood pressure, detect infectious diseases markers, and even perform ECGs. Their easy-to-use and portable devices are medical grade, clinically validated, and digitally enabled, with results available instantly. HealthCube is an ISO 13485 certified company which has received certification from Central Drugs Standard Control Organization (CDSCO) and European CE. HealthCube is backed by global marquee investors including Alkemi Ventures, Perot-Jain Ventures, Acumen, and SV Latam Capital. As of date, over one million beneficiaries have been registered on HealthCube Ecosystem and 2.5 million tests have been performed.

MY01

MY01 is a state-of-the-art medical device geared towards aiding in the detection of Compartment Syndrome (CS); a limb-threatening muscle condition that occurs within 48 hours following trauma. Currently, ACS is diagnosed based on subjective and unreliable outcomes like pain (known as 6 P`s), which when present cannot confirm the diagnosis in time for effective intervention. This leads to increased complications (muscle necrosis/amputation) and costs the US healthcare system more than $2.25 B annually. MY01 is capitalizing on a proven correlation between sustained increase in Intramuscular pressures and ACS for objective, early diagnosis. MY01 operationalizes muscular pressure monitoring into a simple, accurate single-use device. MY01. The simple solution to a dangerous problem.